2bPrecise, a wholly owned subsidiary of Allscripts, has launched a precision medicine initiative at the National Institutes of Health. In this program, NIH researchers will be early adopters of the platform.
The EMR-agnostic 2bPrecise solution analyzes genomic, clinical and lifestyle data to provide actionable and patient-specific information within a provider's existing workflow. The platform will be used across the National Human Genome Research Institute, the National Cancer institute and the NIH Clinical Center.
"We are honored and excited to work with NIH, one of the most innovative research institutions in the world, on this dimensional change of healthcare. 2bPrecise will soon be able to take a big step toward bringing an easy-to-use, clinical-genomic solution into the mainstream," said 2bPrecise General Manager Assaf Halevy, in a statement.
More articles on genomics:
Stanford to use Google Genomics storage in precision medicine research
Carnegie Mellon University develops algorithm for cancer genome analysis
Viewpoint: Privatized data contributes to health inequities, slow scientific progress